AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30213672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical activity level
Number of subjects: 118
Study 30213672 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy for exercise
Number of subjects: 118
Study 30213672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative disability
Number of subjects: 118
Study 30213672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 118
Study 27633962 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 84
Study 27633962 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 84
Study 27633962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 27633962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance
Number of subjects: 84
Study 25948287 — intervention group
Group type: EXPERIMENTAL
Intervention: healthy lifestyle psychoeducational program + improved primary care usual treatment (ITAU)
Number of subjects: 240
Study 25948287 — intervention group
Group type: EXPERIMENTAL
Intervention: focused program on positive affect promotion + ITAU
Number of subjects: 240
Study 25948287 — intervention group
Group type: EXPERIMENTAL
Intervention: mindfulness + ITAU
Number of subjects: 240
Study 25948287 — intervention group
Group type: COMPARATOR
Intervention: ITAU
Number of subjects: 240
Study 23579244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire‐9 (PHQ‐9)
Number of subjects: 1392
Study 23579244 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAMS‐6
Number of subjects: 1392
Study 23579244 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAMS‐3D
Number of subjects: 1392
Study 23579244 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAMS‐3A
Number of subjects: 1392
Study 23579244 — intervention group
Group type: COMPARATOR
Intervention: Structured Clinical Interview for the DSM‐IV (SCID)
Number of subjects: 1392
Study 23579244 — intervention group
Group type: COMPARATOR
Intervention: Hamilton Rating Scale for Depression
Number of subjects: 1392
Study 21262099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of mometasone furoate (MF)
Number of subjects: 40
Study 21262099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20144173 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavone medication
Number of subjects: 40
Study 20144173 — intervention group
Group type: COMPARATOR
Intervention: Non-medication group
Number of subjects: 40
Study 17710979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia with intrathecal fentanyl 25 mcg
Number of subjects: 50
Study 17710979 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 0.25% 10 ml
Number of subjects: 50
Study 16524973 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation followed by surgery (arm A)
Number of subjects: 451
Study 16524973 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of chemoradiation (arm B)
Number of subjects: 451
Study 12658373 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 162
Study 12658373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 10551072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by 2 implants with ball attachments
Number of subjects: 110
Study 10551072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by 2 implants with an interconnecting bar
Number of subjects: 110
Study 10551072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by 4 interconnected implants
Number of subjects: 110
Study 8903117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary insulin (100 U ml-1 as an aerosol by oral inhalation after a 12-h fasting)
Number of subjects: 12
Study 1830277 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 19
Study 1830277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 19
Study 6401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sodium tablets
Number of subjects: 18
Study 6401551 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 18
Study 6401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sodium tablets and Placebo tablets
Number of subjects: 18
Study 6401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium restriction
Number of subjects: 18
Study 30814418 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro)
Number of subjects: 0
Study 30814418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30814418 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro) in male participants
Number of subjects: 0
Study 30814418 — intervention group
Group type: COMPARATOR
Intervention: Placebo in male participants
Number of subjects: 0
Study 27539539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, nondairy meal 4 hours before dosing
Number of subjects: 31
Study 27539539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, nondairy meal 2 hours before dosing
Number of subjects: 31
Study 27539539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal containing dairy 2 hours before dosing
Number of subjects: 31
Study 27539539 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 31
Study 26053288 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 2
Study 26053288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 23916502 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 605
Study 23916502 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 605
Study 23916502 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 605
Study 21697773 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI elimination (everolimus with CNI elimination)
Number of subjects: 394
Study 21697773 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI minimization
Number of subjects: 394
Study 21697773 — intervention group
Group type: COMPARATOR
Intervention: Control (continued CNI unchanged)
Number of subjects: 394
Study 21697773 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI elimination (in patients with baseline CrCl > 50 mL/min)
Number of subjects: 394
Study 21697773 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI minimization (in patients with baseline CrCl > 50 mL/min)
Number of subjects: 394
Study 21697773 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 394
Study 20166586 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine
Number of subjects: 43
Study 16805744 — intervention group
Group type: EXPERIMENTAL
Intervention: One-man method
Number of subjects: 80
Study 16805744 — intervention group
Group type: COMPARATOR
Intervention: Two-man method
Number of subjects: 80
Study 15530762 — intervention group
Group type: EXPERIMENTAL
Intervention: Video colposcopy intervention
Number of subjects: 81
Study 15530762 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 12964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressings (Comfeel Plus, DuoDerm CGF, OpSite)
Number of subjects: 10
Study 12964332 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 10
Study 12964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressings
Number of subjects: 10
Study 9046892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (n = 561)
Number of subjects: 2024
Study 9046892 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (n = 473)
Number of subjects: 2024
Study 9046892 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 990)
Number of subjects: 2024
Study 8378746 — intervention group
Group type: EXPERIMENTAL
Intervention: Very long-chain n-3 fatty acids (0.65 g day-1)
Number of subjects: 24
Study 8378746 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 24
Study 3535007 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg) plus antacid
Number of subjects: 55
Study 3535007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg) plus antacid
Number of subjects: 55
Study 29149437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose [15 mg/kg (up to 750 mg)], intravenously on study days 0 and 5
Number of subjects: 80
Study 29149437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 cc normal saline), intravenously on study days 0 and 5
Number of subjects: 80
Study 29149437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 80
Study 29149437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27098300 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training after AbobotulinumtoxinA injection
Number of subjects: 22
Study 27098300 — intervention group
Group type: COMPARATOR
Intervention: Control group (only AbobotulinumtoxinA injection)
Number of subjects: 22
Study 26178888 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation
Number of subjects: 205
Study 26178888 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face home visit
Number of subjects: 205
Study 23945458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (n = 30)
Number of subjects: 60
Study 23945458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60
Study 21172701 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia and sedation (EMLA 5% cream, midazolam/nitrous oxide)
Number of subjects: 76
Study 21172701 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with or without penile block (sevoflurane, ropivacaine)
Number of subjects: 76
Study 18489932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in patients with normal BMI (<25 kg/m²)
Number of subjects: 607
Study 18489932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in overweight patients (≥25 and ≤30 kg/m²)
Number of subjects: 607
Study 18489932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in obese patients (>30 kg/m²)
Number of subjects: 607
Study 17166340 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 0.5 mg
Number of subjects: 500
Study 17166340 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 1.0 mg
Number of subjects: 500
Study 17166340 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 2.0 mg
Number of subjects: 500
Study 17166340 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 3.0 mg
Number of subjects: 500
Study 17166340 — intervention group
Group type: COMPARATOR
Intervention: pioglitazone 45 mg
Number of subjects: 500
Study 17166340 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500
Study 12648197 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 30
Study 12648197 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 30
Study 12589230 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin combination therapy
Number of subjects: 92
Study 10548357 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine (Tagamet HB)
Number of subjects: 20
Study 10548357 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of Mylanta (initial 17.5-ml dose with additional doses as needed)
Number of subjects: 20
Study 8740603 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity TENS
Number of subjects: 60
Study 8740603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity TENS
Number of subjects: 60
Study 8740603 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 1918785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg every 12 hours or 400 mg every 12 hours during acute phase, followed by 750 mg orally every 12 hours during convalescence phase)
Number of subjects: 50
Study 1918785 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g every 24 hours during acute phase, followed by 1 g intramuscularly every 24 hours during convalescence phase)
Number of subjects: 50
Study 1918785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 50
Study 1918785 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 50
Study 6821904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine, 15 micrograms/kg/min
Number of subjects: 8
Study 6821904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine, 15 micrograms/kg/min
Number of subjects: 8
Study 6821904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine and Dobutamine combination, 7.5 micrograms/kg/min each
Number of subjects: 8
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (1 mg/kg intravenous)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (5 mg/kg intravenous)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20 mg/kg intravenous)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (40 mg/kg intravenous)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (5 mg/kg subcutaneous)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20 mg/kg intravenous, 3 doses at 12-week intervals)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (5 mg/kg subcutaneous, 3 doses at 12-week intervals)
Number of subjects: 26
Study 31473167 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (all groups)
Number of subjects: 26
Study 29693495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (n=37)
Number of subjects: 81
Study 29693495 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (n=44)
Number of subjects: 81
Study 26822749 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (4 mg/kg or 6 mg/kg per day for 3 months)
Number of subjects: 86
Study 26822749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 26822749 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin vs Placebo
Number of subjects: 86
Study 26822749 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 86
Study 24449739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 24
Study 24449739 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control)
Number of subjects: 24
Study 22855753 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated plastic sheeting (ITPS)
Number of subjects: 0
Study 22855753 — intervention group
Group type: COMPARATOR
Intervention: Untreated polyethylene sheeting (UPS)
Number of subjects: 0
Study 20712506 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdependent self‐construal priming
Number of subjects: 58
Study 20712506 — intervention group
Group type: COMPARATOR
Intervention: Independent self‐construal priming
Number of subjects: 58
Study 20712506 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic promotion regulatory focus: high
Number of subjects: 58
Study 20712506 — intervention group
Group type: COMPARATOR
Intervention: Chronic promotion regulatory focus: low
Number of subjects: 58
Study 17573387 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day UDCA
Number of subjects: 596
Study 17573387 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day UDCA
Number of subjects: 596
Study 17573387 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day UDCA
Number of subjects: 596
Study 17573387 — intervention group
Group type: COMPARATOR
Intervention: Control (no UDCA)
Number of subjects: 596
Study 15728282 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 250 microg
Number of subjects: 205
Study 15728282 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1b 50 microg
Number of subjects: 205
Study 15728282 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 205
Study 11888459 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial matrix excision (matrix group)
Number of subjects: 58
Study 11888459 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolization (phenol group)
Number of subjects: 58
Study 10723507 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine once daily
Number of subjects: 0
Study 10723507 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine once daily in combination with other drugs
Number of subjects: 0
Study 7646766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymotrypsin-galactose (CG) treatment of sperm
Number of subjects: 0
Study 7646766 — intervention group
Group type: COMPARATOR
Intervention: Culture medium treatment of sperm
Number of subjects: 0
Study 2649628 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted CBM group
Number of subjects: 30
Study 2649628 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncomputer CBM group
Number of subjects: 30
Study 2649628 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM groups (computer‐assisted and noncomputer)
Number of subjects: 30
Study 2649628 — intervention group
Group type: COMPARATOR
Intervention: Contrast group
Number of subjects: 30
Study 333082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% phenylephrine hydrochloride
Number of subjects: 45
Study 333082 — intervention group
Group type: COMPARATOR
Intervention: 0.5% phenylephrine hydrochloride
Number of subjects: 45
Study 333082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29886273 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 140
Study 28179035 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Number of subjects: 25
Study 28179035 — intervention group
Group type: COMPARATOR
Intervention: Active stimulation
Number of subjects: 25
Study 28179035 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study 25535650 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly (QW)
Number of subjects: 372
Study 23981017 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and prednisolone combined (N = 32)
Number of subjects: 64
Study 23981017 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone monotherapy (N = 32)
Number of subjects: 64
Study 23981017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 21380980 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week (aerobic+strength) exercise training program (3 sessions/week, 90 min/session)
Number of subjects: 16
Study 21380980 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 16
Study 21380980 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week (aerobic+strength) exercise training program
Number of subjects: 16
Study 18312755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 490
Study 18312755 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count
Number of subjects: 490
Study 16564594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 22
Study 12667970 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling LI4 with manipulation
Number of subjects: 13
Study 12667970 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling LI4 without manipulation
Number of subjects: 13
Study 12667970 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling nonacupoint with manipulation
Number of subjects: 13
Study 12667970 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling nonacupoint without manipulation
Number of subjects: 13
Study 12667970 — intervention group
Group type: COMPARATOR
Intervention: Inactive laser to LI4
Number of subjects: 13
Study 11334653 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959
Study 11334653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study 9426377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg p.o., 60 min before OGTT)
Number of subjects: 16
Study 9426377 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose load (OGTT, 100 g p.o. at 0 min) alone
Number of subjects: 16
Study 8179648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 580
Study 8179648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 3432378 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopic luminance sensitivity
Number of subjects: 3
Study 3432378 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotopic luminance sensitivity
Number of subjects: 3
Study 3432378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temperatures
Number of subjects: 3
Study 2403908 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily before breakfast
Number of subjects: 153
Study 2403908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 31116913 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided drug-eluting stent (DES) implantation
Number of subjects: 1443
Study 31116913 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided drug-eluting stent (DES) implantation
Number of subjects: 1443
Study 28490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg twice daily
Number of subjects: 1007
Study 28490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg twice daily
Number of subjects: 1007
Study 28490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg twice daily
Number of subjects: 1007
Study 28490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg once daily (active control)
Number of subjects: 1007